pirtobrutinib news

All news on pirtobrutinib (also known as Jaypirca): plants, production capacities, investments and involved companies.

14 June 2026

Lilly: Jaypirca plus venetoclax‑rituximab lowers progression risk 45% in relapsed/refractory CLL/SLL

Phase 3 BRUIN CLL-322 found adding pirtobrutinib to a two‑year venetoclax+rituximab regimen reduced progression or death by 45% versus venetoclax+rituximab alone.

Who will be producing pirtobrutinib in the future?

Find out with chemXplore Alpha

Learn more